# A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB

> **NCT02333799** · PHASE3 · COMPLETED · sponsor: **Global Alliance for TB Drug Development** · enrollment: 109 (actual)

## Conditions studied

- Pulmonary Tuberculosis

## Interventions

- **DRUG:** Bedaquiline
- **DRUG:** PA-824
- **DRUG:** Linezolid

## Key facts

- **NCT ID:** NCT02333799
- **Lead sponsor:** Global Alliance for TB Drug Development
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2019-01-14
- **Final completion:** 2020-08-03
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2025-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02333799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02333799, "A Phase 3 Trial Assessing Safety and Efficacy of B-Pa-L in Participants With DR-TB". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT02333799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*